A high level of blood IFN-α concentration is also characteristic of autoimmune diseases like dermatomyositis (DM), scleroderma, and systemic lupus erythematosus (SLE).6, 7, 8 In SLE, the systemic level of IFN-α is used as biomarker of disease activity and identifies patients at risk of relapse during remission, making drugs targeting this pathway promising therapeutic options. This evidence concerns the gene IFNA2 and dermatomyositis.